Fate Therapeutics, Inc. (NASDAQ:FATE) expects Q3 2024 earnings per share of ($0.46)

Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) – Equities researchers at Wedbush upped their Q3 2024 earnings per share estimates for Fate Therapeutics in a report issued on Tuesday, August 13th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will earn ($0.46) per share for the quarter, up from their prior estimate of ($0.48). Wedbush has a “Neutral” rating and a $7.00 price objective on the stock. The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.90) per share. Wedbush also issued estimates for Fate Therapeutics’ Q4 2024 earnings at ($0.36) EPS, FY2024 earnings at ($1.62) EPS, Q1 2025 earnings at ($0.38) EPS, Q2 earnings at ($0.38) EPS 2025 at ($0.32) EPS at ($0.32) $3025 EPS Q4 2025 Earnings at ($0.34) EPS FY2025 Earnings at ($1.36) EPS FY2026 Earnings at ($1.27 USD) EPS, FY2027 Earnings at ($1.22) EPS and FY2028 Earnings at ($1.27)

Several other research firms also recently weighed in on FATE. StockNews.com cut Fate Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, May 10th. HC Wainwright reduced their price objective on Fate Therapeutics from $7.00 to $5.00 and set a “neutral” rating for the company in a research report on Thursday, May 16th. Needham & Company LLC reissued a “hold” rating on shares of Fate Therapeutics in a research report on Wednesday. BMO Capital Markets cut their price objective on Fate Therapeutics from $7.00 to $6.00 and set a “market perform” rating for the company in a research report on Friday, May 10th. Finally, Canaccord Genuity Group decreased their price objective on Fate Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Friday, 10 May. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $6.73, according to MarketBeat.com.

Get the latest analysis on FATE

Fate Therapeutics trading up 0.3%

FATE opened at $3.40 on Friday. Fate Therapeutics has a 1 year low of $1.63 and a 1 year high of $8.83. The stock has a market cap of $387.03 million, a price-to-earnings ratio of -1.77 and a beta of 1.90. The company has a 50-day moving average of $3.92 and a 200-day moving average of $5.11.

Fate Therapeutics (NASDAQ:FATE – Get Free Report ) last announced its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.14. The firm had revenue of $6.77 million during the quarter, compared to analysts’ expectations of $1.47 million. Fate Therapeutics had a negative return on equity of 46.49% and a negative net margin of 2,933.79%.

Institutional inputs and outputs

Several hedge funds have recently bought and sold shares of FATE. Assenagon Asset Management SA boosted its stake in Fate Therapeutics by 1,462.4% in the first quarter. Assenagon Asset Management SA now owns 2,548,304 shares of the biopharmaceutical company’s stock worth $18,705,000 after purchasing an additional 2,385,207 shares in the last quarter. BROS bakery. Advisors LP purchased a new stake in shares of Fate Therapeutics in the first quarter valued at $13,345,000. Deerfield Management Company LP Series C boosted its stake in Fate Therapeutics by 62.3% in the second quarter. Deerfield Management Company LP Series C now owns 3,555,871 shares of the biopharmaceutical company’s stock valued at $11,663,000 after buying an additional 1,365,463 shares during the last quarter. Vestal Point Capital LP bought a new position in Fate Therapeutics in the fourth quarter valued at about $4,825,000. Finally, Dimensional Fund Advisors LP boosted its holdings in Fate Therapeutics by 100.4% in the second quarter. Dimensional Fund Advisors LP now owns 2,130,280 shares of the biopharmaceutical company’s stock valued at $6,987,000 after acquiring an additional 1,067,101 shares during the last quarter. 97.54% of shares are currently owned by institutional investors and hedge funds.

Fate Therapeutics Company Profile

(Get a free report)

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company’s chimeric antigen receptor (CAR)-targeted NK and T cell candidates include FT576 to treat multiple myeloma and FT522 to treat lymphoma and autoimmune disorders.

See Also

Get news and reviews for Fate Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Fate Therapeutics and related companies with MarketBeat.com ‘s FREE daily email newsletter.